Browsing Tag
Anish Bhatnagar
1 post
Could Neurocrine’s $2.9bn Soleno deal turn VYKAT XR into its next rare-disease blockbuster?
Neurocrine is buying Soleno for $2.9 billion to add VYKAT XR. Read what the deal means for NBIX growth, rare-disease strategy, and investor sentiment.